Market Overview

Bank of America Merrill Lynch Reiterates Buy Rating, $64 PT on Quest Diagnostics

Share:
Related DGX
The Market In 5 Minutes
Benzinga's Top Upgrades, Downgrades For April 21, 2017
Portfolio —– Investments Buys Moody'soration, The Priceline Group, Visa, Sells American ... (GuruFocus)

In a report published Wednesday, Bank of America Merrill Lynch reiterated its Buy rating and $64.00 price target on Quest Diagnostics (NYSE: DGX).

BofA Merrill Lynch noted, “We were pleased to see DGX follow through on its objective to refocus on its core diagnostic services business, as we continue to believe streamlining the business model, deleveraging, and returning more to shareholders sooner is the right response to a challenging industry environment. Near term, commercial and government reimbursement pressures and light volume will pressure earnings growth, but a few years down the road, expanded health care coverage, a growing focus on outcomes based care, and substantial cost cutting and share repurchases may facilitate a return to double-digit earnings growth and an attractive ROIC profile, in our view. In the interim, our focus is on strong, continuing cash flow. We reiterate our positive outlook.”

Quest Diagnostics closed on Monday at $58.27.

Latest Ratings for DGX

DateFirmActionFromTo
Apr 2017Raymond JamesUpgradesMarket PerformOutperform
Mar 2017Bank of AmericaUpgradesUnderperformNeutral
Jan 2017Deutsche BankInitiates Coverage OnBuy

View More Analyst Ratings for DGX
View the Latest Analyst Ratings

Posted-In: Bank of America Merrill LynchAnalyst Color Reiteration Analyst Ratings

 

Related Articles (DGX)

View Comments and Join the Discussion!